The standard of care for managing patients with type 2 diabetes and CKD -- in addition to a healthy lifestyle -- has always ...

Adding an SGLT2 inhibitor to finerenone in CKD and type 2 diabetes yields “remarkable” albuminuria reductions that may, if ...

Multi-omics analysis of human kidney PDGFRβ+ mesenchymal cells quantified over 14,000 biomolecules across 8 time points, ...

New data from the CONFIDENCE trial demonstrates that combination therapy with finerenone and empagliflozin leads to ...

Patients with diabetic kidney disease (DKD) and anemia have no worse, and possibly better, cardiovascular outcomes from finerenone treatment.

A major international study, being presented today at the 62nd ERA Congress, reveals that the long-accepted survival ...

An analysis of pooled data from two large finerenone trials identified key risk factors for hyperkalemia in patients with CKD ...

primary renal disease, prior organ transplantation, or chronic use of renal function–compromising medication. Special care was taken to include patients over the full range of severity of CHF. All ...

Traditionally within the purview of rheumatology, gout can appropriately be managed by nephrologists for patients with ...

We are squandering trillions of dollars, often to the detriment of our patients, merely to push a number across some ...

Early kidney damage often shows subtle signs like foamy urine, swelling, and increased nighttime urination. Fatigue, ...

In a world first, Canadian scientists at the CRCHUM, the hospital research center affiliated with Université de Montréal, ...